CN104837810B - 氯胺酮衍生物 - Google Patents

氯胺酮衍生物 Download PDF

Info

Publication number
CN104837810B
CN104837810B CN201380061537.2A CN201380061537A CN104837810B CN 104837810 B CN104837810 B CN 104837810B CN 201380061537 A CN201380061537 A CN 201380061537A CN 104837810 B CN104837810 B CN 104837810B
Authority
CN
China
Prior art keywords
alkyl
amino
oxocyclohexyl
halogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380061537.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837810A (zh
Inventor
J·W·斯莱
W·A·丹尼
J·乔斯
S·A·加米奇
M·G·哈维
L·J·福斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CN104837810A publication Critical patent/CN104837810A/zh
Application granted granted Critical
Publication of CN104837810B publication Critical patent/CN104837810B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
CN201380061537.2A 2012-10-08 2013-10-08 氯胺酮衍生物 Expired - Fee Related CN104837810B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ60288512 2012-10-08
NZ602885 2012-10-08
NZ61120213 2013-05-28
NZ611202 2013-05-28
PCT/IB2013/059191 WO2014057414A1 (en) 2012-10-08 2013-10-08 Ketamine derivatives

Publications (2)

Publication Number Publication Date
CN104837810A CN104837810A (zh) 2015-08-12
CN104837810B true CN104837810B (zh) 2019-08-06

Family

ID=50476991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061537.2A Expired - Fee Related CN104837810B (zh) 2012-10-08 2013-10-08 氯胺酮衍生物

Country Status (13)

Country Link
US (3) US20150259277A1 (enExample)
EP (1) EP2903963A4 (enExample)
JP (2) JP6309957B2 (enExample)
KR (1) KR20150065873A (enExample)
CN (1) CN104837810B (enExample)
AU (1) AU2013328280B2 (enExample)
BR (1) BR112015007647A2 (enExample)
CA (1) CA2922340A1 (enExample)
EA (1) EA201590697A1 (enExample)
HK (1) HK1212673A1 (enExample)
IN (1) IN2015DN03854A (enExample)
MX (1) MX2015004362A (enExample)
WO (1) WO2014057414A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6309957B2 (ja) * 2012-10-08 2018-04-11 オークランド ユニサービシーズ リミティド ケタミン誘導体
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US11827606B2 (en) 2015-11-18 2023-11-28 Spirify Pharma Inc. Phenyl cyclohexanone derivatives and methods of making and using them
US11111210B2 (en) 2015-11-18 2021-09-07 Spirify Pharma Inc. Phenyl cyclohexanone derivatives and methods of making and using them
CN109311801B (zh) 2016-03-25 2022-07-26 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮的晶型和合成方法
JP7167168B2 (ja) 2018-01-10 2022-11-08 エックスダブリューファルマ リミテッド ケタミンのプロドラッグ、組成物及びそれらの使用
WO2019186357A1 (en) * 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN112424157B (zh) * 2018-06-04 2024-02-20 美国政府健康及人类服务部 用于合成和纯化(2r,6r)-羟基去甲氯胺酮的方法
CN112125816A (zh) * 2020-03-17 2020-12-25 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
DE102021105268A1 (de) * 2021-03-04 2022-09-08 Lts Lohmann Therapie-Systeme Ag. Oraler Dünnfilm
AU2022326513B9 (en) 2021-08-13 2025-10-23 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
CN115677444A (zh) * 2022-10-26 2023-02-03 公安部第三研究所 同位素毒品代谢物标记化合物及其制备方法、用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) * 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
GB1134146A (en) * 1967-09-15 1968-11-20 Parke Davis & Co New organic amines and methods for their production
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5866591A (en) 1996-09-11 1999-02-02 Glaxo Wellcome Inc. Stable formulations of remifentanil
CN1441790A (zh) * 2000-01-28 2003-09-10 罗姆和哈斯公司 增强性质的药物
US20040248963A1 (en) 2001-11-23 2004-12-09 Bueno Melendo Ana Belen Prodrugs of excitatory amino acids
ATE492565T1 (de) 2002-01-31 2011-01-15 Randox Lab Ltd Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
CN101309667A (zh) * 2005-09-28 2008-11-19 奥里斯医学股份有限公司 治疗内耳疾病的药用合成物
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
EP2766339B1 (en) 2011-10-14 2021-06-09 The United States Of America, as represented by the Secretary, Department of Health & Human Services The use of (2r, 6r)-hydroxynorketamine and other stereoisomeric hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
JP6309957B2 (ja) * 2012-10-08 2018-04-11 オークランド ユニサービシーズ リミティド ケタミン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Structure–activity relationships for ketamine esters as short-acting anaesthetics;Jiney Jose et al.;《Bioorganic & Medicinal Chemistry》;20130627;第21卷;第5098-5106页 *

Also Published As

Publication number Publication date
CA2922340A1 (en) 2014-04-17
US20190169113A1 (en) 2019-06-06
WO2014057414A9 (en) 2014-12-18
JP2015535847A (ja) 2015-12-17
US20150259277A1 (en) 2015-09-17
AU2013328280B2 (en) 2017-12-21
IN2015DN03854A (enExample) 2015-10-02
US20170190653A1 (en) 2017-07-06
JP2018127466A (ja) 2018-08-16
US10239825B2 (en) 2019-03-26
KR20150065873A (ko) 2015-06-15
EA201590697A1 (ru) 2015-09-30
BR112015007647A2 (pt) 2017-07-04
EP2903963A4 (en) 2016-05-25
MX2015004362A (es) 2015-12-08
JP6309957B2 (ja) 2018-04-11
WO2014057414A1 (en) 2014-04-17
AU2013328280A1 (en) 2015-05-14
EP2903963A1 (en) 2015-08-12
CN104837810A (zh) 2015-08-12
HK1212673A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
CN104837810B (zh) 氯胺酮衍生物
JP6794602B2 (ja) ポリアミド化合物及びその使用
CN116472274B (zh) 氮杂环丁烷基色胺和治疗精神障碍的方法
JP2013523599A (ja) 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途
ES2770978T3 (es) Análogos de morfanos y morfinanos y métodos de uso
JP5860895B2 (ja) ５−メチル−１−（ナフタレン−２−イル）−１ｈ−ピラゾール誘導体
TW201245151A (en) Asymmetric ureas and medical uses thereof
JP2024545931A (ja) Ｌｓｄ誘導体、合成、並びに疾患及び障害の治療のための方法
JP2002500214A (ja) 置換２−ベンジルアミノ−２−フェニル−アセトアミド化合物
JP6321274B2 (ja) トリプル再取込み阻害剤及びそれらの使用方法
CN109071392B (zh) 苯环衍生物及其制备方法和在医药上的应用
JP6949057B2 (ja) 動物及びヒトの抗トリパノソーマならびに抗リーシュマニア薬
CN101223129A (zh) 高度选择性血清素和去甲肾上腺素双重再摄取抑制剂和其用途
ITFI20100001A1 (it) Composti ad efficacia sia analgesica che antiperalgesica.
CN114344313A (zh) 用于预防或治疗神经系统退行性疾病的白桦脂酸衍生物
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
KR20200035077A (ko) 통증 및 통증 관련 상태 치료를 위한 새로운 프로판아민 유도체
CN106795100B (zh) 化合物、药物组合物及其在治疗神经退行性疾病中的用途
HUE024560T2 (hu) Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére
NZ619257B2 (en) Ketamine derivatives
CN116023322A (zh) 一种n-乙酰苯胺类阳离子化合物及其制备方法和应用
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
WO2025231265A1 (en) Combination with alpha-2 adrenergic receptor agonist
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
JPWO1998043977A1 (ja) キノリノモルヒナン誘導体およびその医薬用途

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212673

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1212673

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190806

Termination date: 20211008

CF01 Termination of patent right due to non-payment of annual fee